Views & Analysis | Perspectives on pharma industry issues

Patients

Interview at JPM26 with Alexander Schneider

New hope for ovarian cancer, with Alexander Schneider

Alexander Schneider, CEO of CureLab Oncology, shares how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife.

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Patients

Patient centricity: How pharma can move beyond the buzzwords

One important way that pharma companies can deliver true patient advocacy is by bringing cross-functional experience to the table.

Sales & Marketing

Woman shakes man's hand in hiring process

Changing Faces: Agency and consultancy, January 2026

The pharmaceutical services sector saw a flurry of new executive hires last month, spanning agencies, consultancies, investment firms & a few others.

R&D

Best practices in cardiometabolic trial design: Planning and...

Cardiometabolic disease is not a single entity. It is a broad spectrum of disorders that share common drivers.

Oncology

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

Oncology

ASCO 2024 - Steve Devine

While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.

Oncology

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

Sales & Marketing

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Sales & Marketing

Changing Faces: Agency and consultancy, January 2026

The pharmaceutical services sector saw a flurry of new executive hires last month, spanning agencies, consultancies, investment firms & a few others.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone